Innate immune signaling and gut-liver interactions in non-alcoholic fatty liver disease

Veerle Bieghs, Christian Trautwein

Department of Internal Medicine III, University Hospital, RWTH-Aachen, Germany

Correspondence to: Veerle Bieghs. Department of Internal Medicine III, University Hospital, RWTH Aachen, Pauwelstraße 30, 52074 Aachen, Germany. Email: vbieghs@ukaachen.de.

Abstract: Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome and covers a disease spectrum ranging from steatosis to inflammation, fibrosis, cirrhosis and hepatocellular carcinoma (HCC). The innate immune response in the liver plays an important role during NAFLD progression. In addition, changes in the intestinal microbial balance and bacterial translocation can further affect disease progression. Immune cells in the liver recognize cell damage or pathogen invasion with intracellular or surface-expressed pattern recognition receptors (PRRs), subsequently initiating signaling cascades that trigger the release of factors promoting the inflammatory response during NAFLD progression. Therefore, mechanisms by which cells of the immune system are activated and recruited into the liver and how these cells cause injury and stress are important for understanding the inflammatory response during NAFLD.

Keywords: Liver inflammation; innate immunity; toll-like receptors (TLRs); inflammasome; gut-liver axis

Submitted Sep 23, 2014. Accepted for publication Dec 05, 2014.
View this article at: http://dx.doi.org/10.3978/j.issn.2304-3881.2014.12.04

Introduction

Non-alcoholic fatty liver disease (NAFLD) is a rising worldwide public health problem characterized by a typical sequence of disease stages. Early stages involve lipid accumulation (steatosis) and inflammation, which may proceed to chronic inflammation and compensatory tissue repair, leading to accumulation of collagen and scarring (fibrosis or cirrhosis). Liver cirrhosis is associated with progressive loss of organ function and forms the basis for hepatocellular carcinoma (HCC) development. At a certain stage, liver cirrhosis and HCC are non-reversible, often leaving organ transplantation as the only therapeutic option (1-3). Understanding the molecular mechanisms that control the transition between the disease stages is thus critical for the design of disease-modifying therapies.

In Western countries, the metabolic syndrome was found to be a strong predictor of NAFLD development. Obesity, diabetes, insulin resistance and hyperlipidemia, which are the core characteristic features of the metabolic syndrome, are strongly associated with NAFLD (4-6). The prevalence of non-alcoholic steatohepatitis (NASH), which is characterized by the development of liver inflammation, among a general medical population diagnosed with NAFLD is 30%. These patients have a high likelihood of developing advanced fibrosis and cirrhosis (7,8). Although inflammation is considered as main contributor to hepatic tissue damage during NAFLD progression, it is not well understood how the inflammatory mechanisms are initiated. Our current knowledge suggests that the complex local interactions between the cellular components of the innate immune system and the resident cell types of the liver play an essential role in perpetuating and modulating the inflammatory response in the liver.

The innate immune cells in the liver recognize cell damage or pathogen invasion with intracellular or surface-expressed pattern recognition receptors (PRRs). These receptors detect either damage-associated molecular patterns (DAMPs) released from injured cell, or pathogen-associated molecular patterns (PAMPs) which can be derived from gut-derived microbial products (9,10). Therefore, our working hypothesis is that these DAMPs and PAMPs...
can activate the innate immune system during NAFLD progression, thereby subsequently initiating signaling cascades that trigger the release of factors promoting the inflammatory response. In this review, we will focus on innate immune signaling, gut-liver interactions and the metabolic consequences during NAFLD progression.

**PRR signaling during NAFLD**

Toll-like receptors (TLRs) and NOD-like receptors (NLRs) are well known examples of PRRs. The activation of these PRRs induces the transcription of genes involved in the innate immune responses (9,10). Therefore, PRR signaling can play an important role during NAFLD development.

**Toll-like receptors (TLRs)**

TLRs are expressed on Kupffer cells, endothelial cells, dendritic cells, biliary epithelial cells, stellate cells and hepatocytes in liver. They recognize a wide variety of PAMPs, thereby activating these different cell types and contributing to the inflammatory response. TLRs are structurally characterized by the presence of an individual leucine-rich repeat (LRR) domain in their extracellular domain and a Toll/interleukin (IL)-1 receptor (TIR) domain in their intracellular domain. All 13 members of the TLR-family in mice, except TLR3, associate with a common adaptor molecule, MyD88, through interaction of their intracellular TIR domains to trigger inflammatory responses (11,12). TLR3 and TLR4 utilize an alternative adaptor protein, TRIF, to induce type I IFN. TLR4 requires the association with LPS-binding protein (LBP), CD14 and MD2 to recognize LPS. Upon TLR4 ligation, the intracellular domain of TLR4 recruits TIRAP and MyD88 for MyD88 dependent signaling and TRAM bridges TRIF for MyD88-independent signaling (13,14).

The pathogenesis of NAFLD is associated with TLR-signaling (15). Therefore, we will discuss in the next paragraphs the TLRs (i.e., TLR2, TLR4 and TLR9) that received particular interest in relation to NAFLD.

**Toll-like receptor 2 (TLR2)**

TLR2 recognizes a variety of ligands, including bacterial, fungal, viral and some endogenous substances. Among them, certain components of Gram-positive bacterial cell walls (i.e., peptidoglycan and lipoteichoic acid) are demonstrated to activate TLR2 (12). Since levels of *Firmicutes*, which are Gram-positive bacteria, are elevated during obesity, these ligands are rich in gut microbiota of obese subjects and are associated with NAFLD disease progression. Initial studies demonstrated that the absence of TLR2 signaling was protective in diet-induced NASH in mice (high fat and CDAA diet) (21-23). In contrast, TLR2 deficient mice upon MCD diet exhibit equivalent or more severe NASH as a result of increased TLR4 expression and consequently hypersensitivity to LPS (24,25). Therefore, the difference in gut microbiota may be the reason for the contrasting results in TLR2-signaling and demonstrates how important the microbiome is during NAFLD progression.

**Toll-like receptor 4 (TLR4)**

TLR4 is a receptor for lipopolysaccharide (LPS), which is a cell component of Gram-negative bacteria and has received particular interest in relation to hepatic inflammation and fibrogenesis (13,16). During NAFLD progression, metabolic alterations can affect the gut microbiota and gut permeability, thereby elevating circulating levels of LPS in humans as well as animal models of NAFLD [high fat diet, methionine/choline-deficient diet (MCD) and choline-deficient amino acid-define (CDAA) diet] (17,18). In the liver, Kupffer cells are among the first to be hit by bacterial or sterile insults and contribute to the inflammatory response. Kupffer cells express TLR4 and binding of LPS to this receptor results in activation of NF-κB, MAPK, ERK1, p38, JNK and IRF3 triggering the production of pro-inflammatory cytokines and type I interferon. These pro-inflammatory stimuli contribute to enhanced hepatocyte damage, increased leukocyte infiltration and secretion of pro-fibrogenic cytokines such as TGF-β and PDGF, promoting the activation of hepatic stellate cells and the fibrogenic response (13,16). Moreover, inactivation of TLR4 in mice results in a marked attenuation of steatohepatitis induced by a methionine-/choline-deficient diet (19), and leads to a significant decrease in high fat- and fructose-induced hepatic steatosis (20). Therefore, LPS and gut permeability are highly associated with the development of NAFLD, and TLR4 signaling is important to maintain the balance of inflammatory and fibrogenic signaling in the liver. Blocking TLR4 signaling or inhibiting LPS release from the intestinal microbiota may therefore represent a feasible strategy for the prevention or treatment of NAFLD.

**Toll-like receptor 9 (TLR9)**

Activation of TLR9 signaling gained a lot of interest...
In contrast to the data mentioned above, Henao-Mejia et al demonstrated that Nlrp3 knockout mice on choline-deficient amino acid-defined (CDAA) diet. Nlrp3−/− mice were protected from long-term feeding CDAA-induced hepatomegaly, liver injury, infiltration of activated macrophages and liver fibrosis, while Nlrp3 knock-in mice showed severe liver inflammation, with increased infiltration of activated macrophages and early signs of liver fibrosis. These data were confirmed in patients with NAFLD, demonstrating elevated levels of NLRP3 inflammasome components compared to patients with non-NAFLD (31,33). Moreover, levels of pro-IL1β mRNA in these NAFLD patients correlated with the expression of the fibrosis marker COL1A1, indicating the importance of NLRP3 inflammasome activation during fibrosis development in NAFLD (34).

Caspase 1 activation in Kupffer cells induces pro-inflammatory signaling and hepatic stellate cell activation, which are then responsible for collagen deposition and fibrosis during diet-induced NASH (35,36). In addition, hyperlipidemic Ldlr−/− mice transplanted with caspase1/11-deficient bone marrow cells showed less hepatic inflammation and cholesterol crystals inside Kupffer cells upon high cholesterol high fat diet feeding compared to wild type transplanted mice (37). In line with these data, it has been demonstrated that cholesterol crystallization within hepatocyte lipid droplets and aggregation and activation of Kupffer cells in crown-like structures around such droplets represent an important, novel mechanism for progression of simple steatosis to NASH in both humans and mice (38). Furthermore, Csak et al. demonstrated that both bone marrow-derived and non-bone marrow-derived cells contribute to inflammasome activation in a MyD88-dependent manner in dietary NASH. They demonstrated that AIM2 inflammasome expression and activation were further augmented by TLR9 ligands during NAFLD progression (39). Altogether, these data indicate that inflammasome activation during NASH development is maintaining the inflammatory response in the liver.

In contrast to the data mentioned above, Henao-Mejia et
al. demonstrated that modulation of the intestinal microbiota through multiple inflammasome components is a critical determinant of NAFLD/NASH progression, as well as multiple other aspects of the metabolic syndrome such as weight gain and glucose homeostasis (40). The authors described that NLRP3 and NLRP6 inflammasomes and the effector protein IL-18 negatively regulate NAFLD/NASH progression via alterations in the gut microbiota. They demonstrated in different mouse models that hepatic steatosis as well as inflammation are exacerbated through influx of TLR4 and TLR9 agonists into the portal circulation, leading to enhanced hepatic TNF-α expression that drives NASH progression (40). Thus, altered interactions between the gut microbiota and the host may govern the rate of progression of multiple metabolic syndrome-associated abnormalities, highlighting the central role of the microbiota.

**Gut-liver interactions and the impact of the microbiome on NAFLD progression**

The inflammatory phenotype during NAFLD progression can be attributed to the innate immune system, which is the first line of defence against invading pathogens and is crucial for the overall survival of the host. The liver's strategic location is optimal for the translation of physiological and pathological processes within the gastrointestinal tract into metabolic and immunologic outcomes. Therefore, the intestinal microbiota is a central component of hepatic pathophysiology. Under homeostatic conditions, the interaction between commensal micro-organisms and the hosts PRRs is necessary to locally maintain the intestinal microbial balance. In case of both early- and end-stage liver disease, alterations in the gut microbiota are important for the induction as well as the complications of the disease (41). Therefore, metabolic alterations during NAFLD progression can deregulate the innate immune signaling, thereby triggering bacterial translocation (17,18,42).

The role of gut-derived factors on NAFLD progression has just begun to be investigated. In humans, obesity is the most prevalent risk factor for NAFLD. The intestinal bacterial communities have been shown to be a critical modulator of body weight and body fat composition and correlate with multiple inflammatory and metabolic parameters as well as dietary habits in humans (15). Recent findings demonstrated that small intestinal bacterial outgrowth (SIBO) is a key determinant factor for NAFLD progression and is secondary to low intestinal motility. Furthermore, obese individuals have significantly increased levels of SIBO compared to healthy lean subjects, which is associated with increased gut permeability (18,43,44).

Therefore, these data indicate that bacterial translocation of certain bacterial communities might lead to portal endotoxemia and eventually hepatic injury. Most studies have shown that the levels of *Firmicutes* are increased whereas those of *Bacteroidetes* are decreased in obesity and metabolic disorders in humans as well as rodents. Therefore, an increased *Firmicutes/Bacteroidetes* ratio is a potential phenotype of obesity (15) and one may speculate that a larger amount of TLR2 ligands is delivered to the liver, as *Firmicutes* are Gram-positive bacteria. However, the exact contribution of *Firmicutes* and *Bacteroidetes* to the metabolic syndrome remains unknown (15). The development of obesity and NAFLD is also associated with a decrease in *Akkermansia muciniphila*, which are mucin-degrading bacteria residing in the mucus layer of the intestine (45,46). The proportion of *Akkermansia muciniphila* is inversely correlated with body weight in rodents and humans, and probiotic treatment can increase the abundance of these bacteria and improve metabolic parameters in obese mouse models. In addition, *Akkermansia muciniphila* treatment is able to reverse fat gain, serum LPS levels, gut barrier function and insulin resistance (47). Therefore, *Akkermansia muciniphila* can lead to thinner intestinal mucus layer and gut permeability, thereby allowing the leakage of bacterial components and influencing NAFLD progression.

Gut microbiota can also contribute to liver injury in patients with NAFLD by endogenous alcohol production. This endogenous alcohol can affect intestinal permeability, leading to endotoxemia and NAFLD progression. In children, the levels of *Escherichia* were significantly increased in NASH compared with those in obese control. Patients with NASH also had higher blood ethanol levels than the healthy and obese non-NASH subjects, suggesting a link between gut microbiota, endogenous alcohol and NAFLD progression. However, it is currently unclear whether an increase in *Escherichia* is a common mechanism of adult NASH (48).

Diet is a likely factor in altering gut microbiota composition and consequently playing a role in the observed dysbiosis during NAFLD progression. High fat diets alter gut microbiota composition by altering phyla ratios and promoting growth of *Proteobacteria*, which can lead to an increased pro-inflammatory potential of the microbiota (49). Next to the diets enriched with fat, fructose consumption has also greatly increased in recent years (50-52). Hepatic lipid accumulation and an altered microbiota composition
were observed in mice placed on a high-fructose diet. Furthermore, it has been demonstrated that high-fructose diets result in rapidly reduced expression of tight junction proteins and therefore altering the gut barrier function. Consequently, expression of hepatic TLRs is elevated, thereby promoting the inflammatory response during high fructose consumption (53).

Changes in intestinal motility, the subsequent alteration of the microflora, decreased mucosal integrity and increased intestinal permeability are required for microbial products to translocate from the intestinal lumen to the extra-intestinal space, such as the liver. As a consequence of this defective barrier, elevated PAMP levels can often be detected in systemic circulation of diseased persons and further contribute to inflammation and fibrogenesis via PRR signaling (54).

In liver, Kupffer cells can respond to very low concentrations of microbial products such as LPS via activation of NF-κB and production of pro-inflammatory cytokines (55). This hyper-responsiveness of Kupffer cells to LPS is also observed in high fat diet induced steatosis in mice and is linked to TLR4 signaling and the upregulation of CD14 by a leptin-mediated signal (56). Other liver cells such as hepatic stellate cells, endothelial cells, biliary epithelial cells and hepatocytes can also respond to TLR-agonists, thereby triggering NF-κB signaling and fibrogenesis in the liver. These observations are also confirmed by other studies demonstrating that, in mice, diet-induced metabolic syndrome is absent in germ-free conditions (57). In addition, transfer of microbiota from steatotic mice into germfree mice promoted development of high fat diet-induced steatosis compared to germfree mice given the microbiota of non-steatotic mice (58,59). Such steatosis correlated with dysglycemia, suggesting that the altered microbiota was broadly promoting the metabolic syndrome. Therefore, a central hypothesis proposed by several researchers is that increased levels of PRR activation by gut microbiota play a central role in chronic inflammatory processes in the liver (53).

Altogether, characterization of the (specific) bacterial communities and their metabolites should be investigated in large cohorts of patients and in more detail regarding their impact on NAFLD disease progression.

**Linking inflammation to obesity and metabolic consequences**

Low grade chronic inflammation is fundamental in the progression of NAFLD and is a key feature of obesity. These inflammatory processes involve many components of the classical inflammatory response to pathogens and include systemic increases in circulating inflammatory cytokines and acute-phase proteins, recruitment of leukocytes to inflamed tissues, activation of tissue leukocytes and generation of reparative tissue responses like fibrosis (6,60). These innate immune responses demonstrate the importance of PRRs in activating important stress pathways and disrupting critical metabolic processes implicated in obesity (30). Activation of PRRs can lead to peripheral insulin resistance in the liver, muscle and adipose tissue, promote central leptin/insulin resistance and disrupt neuronal control of energy balance in the hypothalamus, impair insulin secretion in pancreatic islets and promote the pathogenesis of atherosclerosis in blood vessel walls.

Furthermore activated PRRs can affect gut microbiota and permeability, thereby triggering an influx of various microbiota-derived PAMPs into the circulation that activate their corresponding PRRs in many tissues (61). In addition, intestinal microbiota might contribute to NAFLD progression by modifying intestinal bile acids (62). Bile acids mediate communication between the liver and intestine by the absorption of dietary fats and vitamins and by acting as ligands for the nuclear receptor farnesoid X receptor (FXR) and the G-protein-coupled receptor TGR5 (54,63). Therefore, changes in the intestinal microbiota and enterohepatic circulation can influence NAFLD progression.

Immune cells are key players in metabolic homeostasis. They respond to metabolic stress and produce pro- and/or anti-inflammatory mediators to modulate metabolite programs. Immune cells start to infiltrate into the adipose tissue at the onset of weight gain and contribute to and perpetuate the inflammatory response, eventually leading to systemic insulin resistance and development of obesity (30). A similar effect is observed during NAFLD progression, with increases in the number of immune cells infiltrating in the liver and elevated cytokine levels (64). The inflammatory response during NAFLD is further supported by elevated levels of certain metabolites such as fatty acids, ceramides and cholesterol crystals, thereby affecting pathogen-sensing signaling pathways (e.g., TLRs, NLRs, JNK, NFκB) (5,65). Therefore, metabolic stress initiates a feed forward cycle of inflammatory responses, resulting in a state of unresolved chronic inflammation.

**Future perspectives**

The liver is the principal metabolic regulator of the body.
Therefore, alterations in the homeostatic state of host-microbial interactions in the gastrointestinal tract could potentially lead to severe metabolic and inflammatory pathologies in the liver. Accumulating data demonstrate that PRR signaling and gut microbiota are closely associated with NAFLD progression. Changes in intestinal motility, the subsequent alteration of the microflora, decreased mucosal integrity and increased intestinal permeability are required for microbial products to translocate from the intestinal lumen to the liver, thereby contributing to inflammation and fibrogenesis via PRR signaling (Figure 1). For a better understanding of the impact of the microbiome on the inflammatory response during NAFLD progression, characterization of the (specific) bacterial communities and their metabolites should be investigated in large cohorts of patients and in more detail. The ultimate goal is to restore eubiosis, thereby resulting in restoration of intestinal homeostasis and symbiosis. Therefore, these new insights could potentially lead to new therapeutic approaches for the prevention and/or treatment of NALFD.

Acknowledgements
This work was supported by a grant from the Alexander von Humboldt Foundation (3.3-BEL/1147960 STP) and the German Research Foundation (DFG: BI 1670/2-1 + TR 285/10-1; SFB/TRR57).

Disclosure: The authors declare no conflict of interest.

References
4. Gregor MF, Hotamisligil GS. Inflammatory mechanisms...
of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis. Hepatology 2012;56:118-29.

